DNA Synthesis Market Report 2025

The DNA synthesis market size has grown exponentially in recent years. It will grow from $4.29 billion in 2024 to $5.18 billion in 2025 at a compound annual growth rate (CAGR) of 20.7%. The growth during the historic period can be attributed to the increasing use of DNA synthesis in academic genomic research, greater integration in agricultural biotechnology, rising demand for basic DNA libraries in gene function studies, expanded use of synthetic genes in vaccine development, and growing applications in infectious disease modeling.

The DNA synthesis market size is expected to see exponential growth in the next few years. It will grow to $10.87 billion in 2029 at a compound annual growth rate (CAGR) of 20.4%. The anticipated growth in the forecast period can be attributed to the increasing adoption of AI and automation within DNA synthesis workflows, enhanced collaboration between biotech companies and academic institutions, rising development of DNA-based data storage solutions, a stronger emphasis on environmentally sustainable synthetic biology, and growing government initiatives supporting genomic innovation. Key trends expected during this period include advancements in enzymatic DNA synthesis techniques, deeper integration of cloud-based bioinformatics in synthesis processes, the emergence of decentralized DNA synthesis platforms, innovations in error-correction methods for synthetic genes, and progress in portable, on-demand DNA synthesis devices.

The growing demand for personalized medicine is anticipated to drive the expansion of the DNA synthesis market in the future. Personalized medicine involves tailoring treatment and prevention strategies based on an individual’s genetic makeup, lifestyle, and environment to achieve the best therapeutic results. This demand is increasing mainly due to advances in genomic technologies, which allow for treatments customized to a person’s genetic profile, enhancing effectiveness and minimizing side effects. DNA synthesis plays a crucial role in personalized medicine by enabling the production of custom DNA sequences used in gene editing, diagnostic tools, and precision therapies, thereby supporting more precise, efficient, and individualized healthcare. For example, in February 2024, the Personalized Medicine Coalition, a US-based advocacy organization, reported that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, compared to six approvals in 2022. Consequently, rising demand for personalized medicine is fueling growth in the DNA synthesis market.

Key players in the DNA synthesis market are focusing on creating innovative solutions such as synthetic DNA molecules to enable faster, more accurate, and cost-effective development of gene therapies, diagnostics, and synthetic biology applications. Synthetic DNA molecules are artificially constructed nucleotide sequences designed to replicate or modify natural DNA for use in research, diagnostics, and biotechnology. For instance, in May 2025, Ribbon Biolabs, an Austria-based synthetic biology company, introduced MiroSynth, a new type of complex synthetic DNA molecule. This technology facilitates high-throughput, automated, and scalable production of long, intricate DNA sequences for advanced biotech applications. MiroSynth offers enhanced accuracy in assembling sequences, the ability to create longer strands, and rapid construction of complex genetic structures, making it ideal for research, therapeutic development, and industrial biotech. Its adaptable design allows integration into various workflows, helping researchers and developers accelerate innovation in genomics, synthetic biology, and personalized medicine.

In February 2025, Maravai LifeSciences, a US-based life sciences company, acquired the DNA and RNA business of Officinae Bio for an undisclosed sum. This acquisition is intended to bolster Maravai’s position in the nucleic acid production market by expanding its capabilities in high-quality DNA and RNA synthesis. Officinae Bio is an Italy-based biotechnology firm specializing in the development and manufacturing of DNA and RNA for research and therapeutic purposes.

Major players in the DNA synthesis market are Thermo Fisher Scientific Inc., Eurofins Scientific, GenScript Biotech Corporation, Twist Bioscience Corporation, Bioneer Corporation, DNA Script, Eton Bioscience, LGC Biosearch Technologies, Ansa Biotechnologies, Synbio Technologies, Quintara Biosciences, BaseClear B.V., IBA GmbH, Elegen Corporation, Biomatik Corporation, Bio Basic Inc., Evonetix Ltd., Camena Bioscience Ltd., Jena Bioscience GmbH, and Viridos.

North America was the largest region in the DNA synthesis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in DNA synthesis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the DNA synthesis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The DNA synthesis market consists of revenues earned by entities by creating synthetic DNA sequences for use in research, diagnostics, therapeutics, and biotechnology applications. The market value includes the value of related goods sold by the service provider or included within the service offering. The DNA synthesis market includes sales of custom DNA oligonucleotides, gene synthesis kits, reagents, and associated synthesis tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The DNA synthesis market research report is one of a series of new reports that provides DNA synthesis market statistics, including the DNA synthesis industry global market size, regional shares, competitors with the DNA synthesis market share, detailed DNA synthesis market segments, market trends, and opportunities, and any further data you may need to thrive in the DNA synthesis industry. This DNA synthesis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

DNA synthesis refers to the natural or laboratory-based process of creating a new strand of deoxyribonucleic acid. Naturally, it takes place during cell division when DNA replicates to transfer genetic information to daughter cells. In biotechnology, DNA synthesis also involves the chemical fabrication of custom DNA sequences within a laboratory setting.

The primary types of DNA synthesis services include oligonucleotide synthesis, standard oligonucleotide synthesis, custom oligonucleotide synthesis, gene synthesis, custom gene synthesis, and gene library synthesis. Oligonucleotide synthesis is the chemical creation of short nucleotide sequences (oligonucleotides) used in genetic testing, research, diagnostics, and therapeutic applications. Various techniques are employed, including solid-phase synthesis, PCR-based enzymatic synthesis, and chip-based synthesis. These synthesized sequences find applications in research and development, diagnostics, therapeutics, synthetic biology, and more. The main end users encompass pharmaceutical and biotechnology companies, contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), academic and research institutions, and others.

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.